Appendix Table F-2. Study characteristics—KQ 2

| **Study:**  **Author**  **Year**  **Acronym** | **Study Design; Setting;**  **Location;**  **Funding Source;**  **Quality** | **Tools Assessed** | **Total N** | **Mean Follow up period** | **Mean Age (years)** | **Special Population** |
| --- | --- | --- | --- | --- | --- | --- |
| Apostolakis, 2012[39](#_ENREF_39)  AMADEUS | RCT;  NR;  US, Canada, UK, Europe, Australia/NZ;  Industry;  Low risk of bias | HEMORR2HAGES  HAS-BLED  ATRIA | 2,293 | Total: 429 days (+/- 118) | Total: 70.2  (SD 9.1) | None |
| Friberg, 2012[1](#_ENREF_1)  Swedish Atrial Fibrillation cohort study | Prospective cohort;  Inpatient, Outpatient;  Europe;  Government, Nongovernment, Nonindustry;  Low risk of bias | CHADS2 score  CHA2DS2-VASc score  Framingham score  HAS-BLED  HEMORR2HAGES | 170,291 | Total: Median 1.4 yr (IQR 1.8) | Total: 76.2 | None |
| Gallego, 2012[40](#_ENREF_40) | Retrospective cohort;  Outpatient;  Europe, NR;  Government;  Unclear | HAS-BLED | 965 | Total: Median 861 days | Total: Median 76 (IQR 70-81) | Patients in the therapeutic range |
| Lip, 2012[41](#_ENREF_41)  Loire Valley Atrial Fibrillation Project | Retrospective cohort;  Inpatient;  Europe;  NR;  Unclear | HAS-BLED  HEMORR2HAGES  ATRIA  Bleeding Risk Index | 7,156 | NR | Arm 1:  77.7 (SD 8.2)  Arm 2:  73.8 (SD 11.6)  Arm 3:  49.0 (SD 13.1) | None |
| Naganuma, 2012[3](#_ENREF_3) | Retrospective cohort;  Outpatient;  Asia  Nongovernment, Nonindustry;  Low risk of bias | CHADS2 score - Low  HAS-BLED - Unclear | 845 | Total: Median 27 mo | Total: Median 74 | None |
| Roldan, 2012[42](#_ENREF_42) | Retrospective cohort;  Outpatient;  Europe;  NR;  Unclear | ATRIA  HAS-BLED | 937 | Total: Median 952 days (IQR 785-1074) | Total: Median 76 (IQR 70-81) | Patients in the therapeutic range |
| Ruiz-Nodar, 2012[8](#_ENREF_8) | Retrospective cohort;  NR;  Europe;  NR;  High risk of bias | HAS-BLED  CHA2DS2-VASc score | 590 | Total: ~12 mo | Total: 72.2  (SD 8.1) | None |
| Fang, 2011[43](#_ENREF_43)  ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) | Retrospective cohort;  Outpatient;  US;  Government, Industry, Nongovernment, Nonindustry;  Low risk of bias | ATRIA  HEMORR2HAGES  Bleeding Risk Index | 9,186 | Total: Median 3.5 yr (IQR 1.2-6.0) | NR | None |
| Lind, 2011[2](#_ENREF_2) | Retrospective cohort;  Outpatient;  Europe;  NR;  High risk of bias | INR | 19,180 | NR | NR | None |
| Lip, 2011[44](#_ENREF_44)  SPORTIF (Stroke Prevention using an ORal Thrombin Inhibitor in atrial  Fibrillation) | RCT;  Outpatient;  NR;  Industry;  Low risk of bias | HAS-BLED  CHADS2 score | 7,329 | NR | Arm 1: 73.9 (SD 8.6)  Arm 2: 70.9 (SD 8.9) | None |
| Olesen, 2011[11](#_ENREF_11) | Retrospective cohort;  Inpatient;  Europe;  NR;  High risk of bias | CHADS2 score  CHA2DS2-VASc score | 132,372 | Total: Max 12 | Arm 1:  72.8 (SD 14.4)  Arm 2:  70.6 (SD 11.1)  Arm 3:  78.1 (SD 11.2)  Arm 4:  73.1 (SD 9.6) | None |
| Olesen, 2011[45](#_ENREF_45) | Retrospective cohort;  Inpatient;  Europe;  NR;  Low risk of bias | HAS-BLED  HEMORR2HAGES | 118,584 | Total: 10 | Arm 1:  78.6 (SD 10.6)  Arm 2:  74.7 (SD 13.6)  Arm 3:  74.6 (SD 9.2)  Arm 4:  71.2 (SD 10.7)\_ | None |
| Poli, 2011[13](#_ENREF_13) | Prospective cohort;  NR;  Europe;  None;  Low risk of bias | CHADS2 score  Bleeding Risk Index | 3,302 | Total: Median 2.3 (IQR 0.8 to 4.4) | Total: Median 74 (IQR 68 to 80) | None |
| Pisters, 2010[46](#_ENREF_46)  Euro Heart Survey for AF | Prospective cohort;  Inpatient, Outpatient;  Europe;  Industry;  Low risk of bias | HAS-BLED  HEMORR2HAGES | 3,456 | Total: ~1 yr | 66.8 (SD12.8) | None |
| Gage, 2006[47](#_ENREF_47)  NRAF (National Registry of Atrial Fibrillation) | Retrospective cohort;  Outpatient;  US;  Government, Nongovernment, Nonindustry;  Low risk of bias | HEMORR2HAGES  Bleeding Risk Index | 3,791 | Total: 0.82 yr (3138 pt-yrs/3791 yrs) | Total: 80.2 | None |
| Shireman, 2006[48](#_ENREF_48) | Retrospective cohort;  Outpatient;  US;  Government;  Low risk of bias | Bleeding Risk Index | 26,345 | NR | NR | None |
| Aspinall, 2005[49](#_ENREF_49) | Retrospective cohort;  Outpatient;  US;  None;  Low risk of bias | Bleeding Risk Index | 1,269 | NR | Total:  67.9 (SD 11.4) | None |
| Hylek, 2003[34](#_ENREF_34)  ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) | Retrospective cohort;  Outpatient;  US;  Government;  Low risk of bias | INR | 596 | NR | Arm 1: 79  Arm 2: 80  Arm 3: 76 | Patients with prior stroke |

**Abbreviations:** AF = atrial fibrillation; IQR = interquartile range; N = number of patients; NR = not reported; RCT = randomized controlled trial; SD = standard deviation